A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation ( <scp>PROGESTWIN</scp> ): evidence for reduced neonatal morbidity

Abstract

Intramuscular 17OHPC therapy did not reduce PTB before 37 weeks of gestation in unselected twin pregnancies. Nonetheless, 17OHPC significantly reduced neonatal morbidity parameters and increased birthweight.